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Abstract
Background: Care for malaria patients in endemic areas has been improved through the increasing use of Rapid Diagnostic
Tests (RDTs). Most RDTs target the histidine-rich protein-2 antigen (PfHRP2) to detect P. falciparum, as it is abundant and
shows great heat stability. However, their use in South America has been widely questioned following a recent publication
that pinpoints the high prevalence of Peruvian field isolates lacking the gene encoding this protein. In the remote rural
health centers of French Guiana, RDTs are the main diagnosis tools. Therefore, a study of PfHRP2 RDT performances and
pfhrp2 genotyping was conducted to determine whether a replacement of the current pLDH-based kit could be considered.
Methods: The performance study compared the SD Malaria Ag test P.f/PanH kit with the current gold standard diagnosis by
microscopy. The prevalence of pfhrp2 and pfhrp3 deletions were evaluated from 221 P. falciparum isolates collected
between 2009 and 2011 in French Guiana.
Results: Between January 2010 and August 2011, 960 suspected cases of malaria were analyzed using microscopy and RDTs.
The sensitivity of the SD Malaria Ag test P.f/PanH for detection of P. falciparum was 96.8% (95% CI: 90.9–99.3), and 86.0%
(95% CI: 78.9–91.5) for the detection of P. vivax. No isolates (95% CI: 0–4.5) lacking either exon of the pfhrp2 gene were
identified among the 221 P. falciparum isolates analyzed, but 7.4% (95% CI: 2.8–15.4) lacked the exon 2 part of the pfhrp3
gene.
Conclusions: Field isolates lacking either exon of the pfhrp2 gene are absent in this western part of South America. Despite
its sensibility to detect P. vivax, the SD Malaria Ag test P.f/PanH kit is a satisfying alternative to microscopy in remote health
centers, where it is difficult to provide highly skilled microscopists and to maintain the necessary equipment.
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Introduction
In the late 1990’s, the introduction of Rapid Diagnosis Tests
(RDT) for malaria provided a rapid, accurate and accessible
diagnostic tool that reduced clinical diagnosis in endemic areas
where skills and materials are lacking. As malaria symptoms are
non-specific, this lowered presumptive treatment and therefore
reduced drug pressure on the parasite population. Numerous
commercial kits exist. WHO therefore evaluated the performances
of a wide panel of commercial kits, using a standardized procedure
in order to compare performances between them. The results of
these evaluations have been published and included in general
guidance for health workers [1–4]. The selection of an appropriate
RDT in a given region is based on the epidemiology of malaria
and the performances of the kit in that particular area [5].
French Guiana is an outermost region of France located in
Amazonia between North Brazil and Suriname. The health system
in this region consists of a network of medical structures that allow
patients to be treated close to their homes. The Hospital of
Cayenne, the main town of French Guiana, administers these
rural health-posts, which are spread over the entire territory. In
the smallest of these healthcare facilities, the health provider team
is composed of just one nurse. In this Amazonian area, malaria is
endemic. In 2011, P. falciparum and P. vivax represented 31% and
68.5% of the 1,205 cases, respectively [6]. P. malariae cases are
occasional. Transmission occurs along thousands of miles of rivers
with a low number of focal points in the coastal area where the
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majority (90%) of the population lives. This transmission is closely
linked with the mostly illegal gold mining activities [7,8]. In this
context, the containment of the disease in these areas is difficult.
Until 2000, malaria diagnosis using microscopy was widespread in
French Guiana. However, owing to the difficulty of maintaining
highly skilled microscopists in these remote rural areas and the
frequent need for the maintenance of equipment, this gold
standard method was replaced by RDT for malaria in some of the
health-posts.
RDTs for malaria are specific for one of the three following
antigens: Histidine Rich Protein 2 (only produced by P. falciparum,
PfHRP2), Lactate Dehydrogenase (pLDH) or aldolase. P.
falciparum secretes three histidine-rich proteins that share repeats
of hexapeptides representing the epitopes, and they are recognized
by monoclonal antibodies (Mab) raised against PfHRP2 protein.
Cross-reactions may therefore occur between the PfHRP2 specific
Mab and epitopes of the PfHRP3 protein. These hexapeptides are
encoded by the exon 2 part of the gene, which is very polymorphic
among isolates [9,10]. This polymorphism could therefore affect
the performances of these RDTs [9,11]. The pLDH-pan antigen is
common to all malaria species but some antigen epitopes are
species specific (pLDH-pf for P. falciparum; pLDH-pv for P. vivax)
[12]. The antibody composition of RDTs is thus a key factor in
whether the test differentiates the malaria species or not. In French
Guiana, the Optimal-ITH kit (pLDH-pan + pLDH-pf) has been
used by health posts since the introduction of RDTs in the malaria
diagnosis policy in 2000. However, owing to its relatively low
sensitivity for the detection of P. falciparum, and the recent
commercialization of several new kits, the authorities are currently
considering switching to the pLDH-pan + PfHRP2 kit. HRP2-
based RDTs are indeed more suitable for the diagnosis of P.
falciparum because of their higher sensitivity, better stability across a
wider temperature range and lower cost [3,13].
Recently, up to 41% of parasites in Peru were reported to lack
the pfhrp2 gene [14–16]. These genomic particularities could lead
to the misidentification of the species when HRP2 RDTs are used
for malaria diagnosis. In French Guiana, this was the case in 2009
for a patient with 0.4% P. falciparum parasitemia (sample M618),
which was wrongly diagnosed by HRP2 RDTs as ‘‘species
different from P. falciparum’’ and treated by chloroquine. Owing
to the prevalence of chloroquino-resistant parasites (25%) in this
region, this could have had serious consequences for the patient
[17]. In this context, we therefore evaluated the prevalence of this
histidine-rich protein gene family (either exon of the pfhrp2 gene
and pfhrp3 exon 2) in parasites from French Guiana and its
consequences on performances of an HRP2-based RDT, the SD
Malaria Ag P.f/PanH kit.
Materials and Methods
Sample Collection
As the National Reference Center (NRC) for Malaria, the
parasitology laboratory of the Institut Pasteur de la Guyane is
responsible for collecting the majority of malarial samples drawn
in French Guiana in order to follow the resistance level of the
parasites to antimalarial drugs. In an attempt to evaluate the
prevalence of the pfhrp2 gene deletion, we first performed a
retrospective study on a total of 140 P. falciparum isolates collected
throughout French Guiana in 2009 (Figure 1). Isolates were
selected according to this year of collection because this was when
Figure 1. Map of French Guiana, part of Amazonia, South America. Figures in brackets are the number of isolates collected in each
health care institution then analysed retrospectively to evaluate the prevalence of pfhrp2 deletion in French Guiana.
doi:10.1371/journal.pone.0074269.g001
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the misidentified M618 isolate was reported. Reference strains
(genotypically characterized using microsatellite markers) were
used as positive and negative controls. These included the
undeleted strains 3D7, 7G8 and W2, the pfhrp2-deleted strain
D10 and the pfhrp3-deleted strain HB3 [15,18].
In a second step, we evaluated the performances of the PfHRP2
based RDT, SD Malaria Ag P.f/PanH (Standard Diagnostics Inc.).
For this purpose, we included febrile patients of all ages who
consulted for suspected malaria during a prospective study. For a
proper assessment of performances (criteria: 95% with a precision
of 5% and an alpha error of 0.05), the number of cases required in
each of the three groups (negative samples, P. falciparum and P.
vivax) was evaluated at 73, and recruitment continued until at least
the required number was reached for each group.
Regular Malaria Diagnosis
Venous blood for malaria diagnosis was taken from 4 ml
samples collected in EDTA tubes.
Reference method. Microscopic examination by an expert
microscopist was considered the reference method for malaria
diagnosis. Thick and thin blood films were prepared within one
hour of blood collection. Thick blood films were stained with
Giemsa diluted at 10%, whilst thin blood films were stained using
a rapid method (RALH 555, RAL Diagnostics). Two hundred
fields of the thin blood film were examined before classifying the
thin smear negative, then 1000 counted white blood cells (WBCs)
from the thick smear were observed before classifying the sample
as negative. The parasite density estimation was based on an
assumed 6,000 WBC/ml of blood.
The microscopic examination results were transmitted to the
appropriate physicians within an hour of the blood being drawn.
In the case of positive results, patients were treated following the
regional guidelines for malaria [19].
Rapid diagnostic tests. The SD Malaria Ag P.f/PanH (Standard
Diagnostics Inc.) detects the presence of pan-pLDH and PfHRP2
antigens. This test was performed according to the manufacturer’s
instructions, and the microscopic examination was carried out
simultaneously by a second technician. Interpretation of the test
results was carried out independently of the microscopic exami-
nation and within the time recommended by the manufacturer.
Test results were considered invalid if no control band was seen.
The tests were guaranteed to have been correctly stored
(temperature 24–28uC) and were used within their recommended
shelf life.
Malaria Diagnosis by PCR
In the case of diagnosis discrepancies between RDT and
microscopy, a PCR method was used to determine the species
present in the sample. DNA was extracted from 200 ml of venous
blood collected from EDTA tubes using the QIAmpH DNA mini
kit (Qiagen). All the manufacturer’s instructions were followed
with the exception of the elution step, which was carried out with
100 ml of elution buffer instead of 200 ml. A nested-polymerase
chain reaction (PCR) was performed for samples with non-
concordant results. Species-specific nested PCR tests were carried
out for each of the four main malaria species, as previously
described [20]. The sensitivity of this method in our laboratory
was evaluated at 2.5 and 1 parasites/ml of blood to detect P.
falciparum and P. vivax, respectively (data not shown).
RDT Performance Evaluation
P. malariae cases were removed from the study. Mixed P.
falciparum/P. vivax infections were analyzed in the P. falciparum
group, as the SD Malaria Ag P.f/PanH only allows the distinction
between P. falciparum and other species. The performances of the
SD Malaria Ag P.f/PanH kit were expressed by calculating the
sensitivity and the specificity for P. vivax and P. falciparum
separately, taking microscopy results as the ‘‘gold standard’’.
Sensitivity is the ability of the test to detect parasites among
samples seen to contain parasites during microscopic examination.
The sensitivity value was the number of P. falciparum or P. vivax
samples showing concordant microscopy and RDT results divided
by the total number of P. falciparum or P. vivax results gained
through microscopy, respectively.
Specificity is the ability of the test to correctly classify negative
samples among negative microscopy results. The specificity value
was the number of samples lacking P. falciparum or P. vivax (i.e.
those containing other malaria species + negative samples) divided
by the total number of negative P. falciparum or P. vivax microscopy
results, respectively.
Data were analyzed using the Epi-info 3.5.1 software (CDC,
Atlanta, GA). Results were accompanied by 95% confidence
intervals (95% CI) calculated using the Clopper Pearson exact
method [21].
Detection of the pfhrp2 and pfhrp3 Genes
We amplified either exon of the pfhrp2 gene and the exon 2 of
the pfhrp3 gene from 2 ml of DNA using the primers and conditions
described in Table 1. The A262/A263 primer pair amplified the
exon1/intron 1 part of the pfhpr2 gene from 10 bp before the start
codon to 305 bp after; the A118/A119 primer pair from 225 bp
after the start codon to 274 bp after the stop codon of the pfhrp2
coding sequence and A266/A261 amplified the exon 2 part of the
pfhrp3 gene from 226 bp after the start codon to 20 bp after the
stop codon. PCR products were analyzed by electrophoresis in
1.5% agarose gel. Sensitivities of these PCRs were evaluated at 25
and 50 parasites/ml of whole blood, respectively (data not shown).
The pfhrp2 gene was sequenced for a panel of 30 P. falciparum
isolates identified during the prospective study. These were
randomly selected with the exception of M618, the isolate of
particular interest. The PCR products obtained after the
amplifications, with the primer pairs A118/A264 and A262/
A263 were purified using spin columns (QIAGEN) then sequenced
using standard dye-terminator sequencing reactions (Applera).
The sequences reported in this article have been deposited in the
GenBank database (accession number KC558574 to KC558602).
Nucleotide sequences were translated to amino acids and each
repeat was identified using a previously-described numeric code
system [9]. The sequences were aligned using the MegaAlignH
software (DNAstarH Lasergene) and categorized into groups and
sub groups according to their similarities.
Ethical Considerations
Analyzed samples were all obtained by blood collections
required by the standard medical care for any patient presenting
fever on hospital admission in French Guiana. According to the
French legislation (article L.1211-2 and related of the French
Public Health Code), biobanking and secondary use for scientific
purpose of human clinical remaining samples are possible as long
as the corresponding patients are informed and has not given any
objection to them. In the present research, this requirement is
fulfilled: information is given to every patient through the Hospital
brochure entitled ‘‘Information for patients’’, and no immediate or
delayed patient opposition was reported by the hospital clinicians
to the Malaria NRC.
Moreover, in application of French legislation (article L.1243-3
and related of the French Public Health Code), samples received
at the Malaria NRC had been registered for research purpose in
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the NRC biobank declared to both the French Ministry for
Research and a French Ethics Committee which both approved
and registered this thematic biobank (declaration number DC-
2010-1223; collection Nu2). No institutional review board
approval is required according to the French legislation.
Results
None of the 140 Isolates Lacked the Entire pfhrp2 Gene
We amplified either exon of the pfhrp2 gene of 140 P. falciparum
isolates collected from different parts of the country in 2009
(Figure 1). The M618 case from Saint Laurent du Maroni was
included in this genotyping. None of these isolates (95% CI: 0–
2.60) contained parasites lacking the pfhrp2 gene. However, 2.86%
(95% CI: 0.78–7.15, n= 4/140) isolates lacked the pfhrp3 exon 2.
The SD Malaria Ag P.f/PanH Kit Demonstrates High
Performances in French Guiana
The prospective study to evaluate the performances of the SD
Malaria Ag P.f/PanH kit was conducted from July 2010 to July
2011. During this period, 960 EDTA blood samples were collected
at Cayenne Hospital from patients with suspected malaria. The
male/female ratio was 1.2:1 with a median age of 25.8 years
[range 1–92 years]. The place of contamination was unknown for
most of the patients. According to the data analysis plan, three P.
malariae cases were excluded and the 7 P. falciparum/P. vivax mixed-
infections detected by microscopy were analyzed as P. falciparum
infection. Microscopic examination revealed the majority of the
samples (n = 738, 77.9%) to be negative for malaria, whilst 93
(9.7%) and 129 (13.4%) isolates were positive for P. falciparum and
P. vivax, respectively (Table 2). The median parasitaemia values
were 0.15% and 0.11% in the P. falciparum and P. vivax positive
samples, respectively. No invalid RDTs (absence of control band)
were observed. The SD Malaria Ag P.f/PanH kit exhibited a
sensitivity of 96.8% (95% CI: 90.9–99.3) to detect P. falciparum and
86.0% (95% CI: 78.9–91.5) to detect P. vivax. The associated
specificities were 98.8% (95% CI: 97.9–99.5) and 99.6% (95% CI:
99.0–99.9) for the diagnosis of P. falciparum and P. vivax,
respectively.
Twenty-eight discrepant results were found between the
microscopic examination and RDT results (Table 2). They were
all analyzed by PCR (Table 3). The microscopic results were
confirmed for 82.1% (n= 23/28) of these cases. In half of the
discrepancies, the SD Malaria Ag P.f/PanH kit had failed to detect
P. vivax isolates. These false negative results were essentially linked
to isolates with a parasite density of less than 0.01% (n= 12/14).
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Table 2. Study of the SD Malaria Ag P.f/panH performances
compared to microscopy as gold standard, French Guiana,
July 2010–July 2011.
Microscopy (n=28 discrepancies)
SD Malaria Ag P.f/panH Pf Pv Negative n
P. falciparum 90 4 6 100
Other Plasmodium sp. 2 111 1 114
Negative 1 14 731 746
Total 93 129 738 960
Entirely concordant results are shown in the grey fields.
doi:10.1371/journal.pone.0074269.t002
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Regarding the discrepancies potentially linked to the pfhrp2
genotype of the parasites, one isolate of interest was identified,
namely N500. PCR validation and a second microscopic
examination determined that it was a mixed infection (Pf/Pv)
missed by both microscopy and the RDT kit. In this isolate, the
pfhrp3 exon 2 was deleted, whilst either exon of the pfhrp2 gene was
present.
As the isolates included in the retrospective study did not
contain any parasites lacking either exon of the pfhrp2 gene, the 93
confirmed P. falciparum samples of the prospective study were
included in a systematic presence/absence of the entire pfhrp2 gene
and pfhrp3 exon 2 genotyping processes. Within these 93 isolates,
ten DNA were not available for analysis, and two isolates were
excluded after PCR confirmed them to be either negative or to
contain P. vivax (Table 3). None (CI95%: 0–4.45) of the 81 isolates
analyzed showed a pfhrp2 gene deletion. In 7.4% (CI95%: 2.77–
15.43, n= 6/81) of cases, a deletion of the exon 2 part of the pfhrp3
gene was observed.
Low Polymorphism in the Pfhrp2 Gene of Parasites
Circulating in French Guiana
For a better understanding of the PfHRP2 polymorphism
displayed by the isolates circulating in French Guiana, 30 samples
were genotyped. Twenty-nine pfhrp2 sequences were obtained and
converted into bar code according to their amino acid repeats.
Finally, haplotypes were categorized in three groups according to
motif similarities (Table 4). The group 1 haplotype prevailed
(82.8% vs 13.8% and 3.4% for the groups 2 and 3 respectively),
and the M618 isolate was part of this group. No polymorphism
was observed in the exon 1 part of the pfhrp2 gene while variability
in the microsatellite included in the intron 1 was observed in two
samples (16 and 18 repeats versus 15 for the others). Furthermore,
no frame shift in the pfhrp2 sequence of these samples was
observed.
Discussion
The present study is the first report carried out in the eastern
part of the Amazonian region to simultaneously assess: i) the
genotype of the histidine-rich protein gene family, and ii) the
associated performances of an HRP2-based RDT kit. It confirms
that these types of RDT are suitable for malaria diagnosis in
French Guiana, as none of the parasites in this part of the world
lack the whole pfhrp2 gene and only 4.5% lacked the pfhrp3 gene.
High Performances of the PfHrp2-based RDT in French
Guiana
In order to be reliable, a method for P. falciparum diagnosis
should provide a sensitivity of over 95% [22]. The PfHRP2-based
kit, SD Malaria Ag P.f/PanH, demonstrated high performances
with sensitivities of 96.8% (95% CI: 90.9–99.3) and 86.0% (95%
CI: 78.9–91.5) for the detection of P. falciparum and P. vivax,
respectively. Comparison with previous studies is difficult, as test
performances may vary due to i) different geographical variations
of parasite populations, ii) levels of disease prevalence and iii) the
study design [13,22]. Nevertheless, the 96.8% sensitivity for the
detection of P. falciparum correlates with previous results obtained
with other PfHRP2 based kits in the region [3,23]. Sensitivity was
lower (86%) in the diagnosis of P. vivax. This value is mainly
explained by the false negative results obtained for isolates with
parasitemia values of under 0.01%. P. vivax cases being generally
more benign than P. falciparum, the SD Malaria Ag P.f/PanH kit
could therefore be considered suitable for malaria diagnosis in
French Guiana.
No Deletion and Limited Polymorphism of the Pfhrp2
Gene in French Guiana
If we consider the entire set of analyzed samples, these
performances were associated with an absence of pfhrp2 gene
deletion (95% CI: 0–1.66, n= 0/221) and 4.5% deletion of the
pfhrp3 exon 2 (CI95%: 2.19–8.16, n= 10/221). This sampling
represented 14.8% (221/1495) of the total numbers of P. falciparum
malaria cases identified in French Guiana on the same period.
Even if the majority of the isolates were collected in Cayenne, a
non-endemic town, local knowledge on human population
movements suggests that malaria samples collected in this town
are from different parts of French Guiana. Therefore, these results
could be extended to the general parasite population circulating in
the region between 2009 and 2011. This absence of pfhrp2 deletion
contrasts with a previous study in the Amazonian region of Peru
[15]. The authors reported a deletion prevalence of over 25% for
the pfhrp2 gene and more than 70% for the pfhrp3 gene. These
results, associated with the very high prevalence of P. vivax in
South America, led WHO to recommend the pLDH-based RDTs
in this part of the world. However, results from other parts of the
continent are scarce [18,24]. The results of this study suggest that
this deletion phenomenon is uncommon in the western part of
South America.
A study was carried out on the genetic variability of this gene,
including exon 2 which encodes the epitopes detected by the
RDTs. No frame shift and a limited genetic diversity were
observed among the 29 analyzed samples. Haplotype 1 was
Table 3. Diagnosis results after analysis by PCR of the discrepancies observed between the SD Malaria Ag P.f/panH assay and
microscopy, French Guiana, July 2010–July 2011.
Microscopy results
Pf Pv Neg
PCR results
RDT Pv Neg Pf Neg Pf Pv n
P. falciparum 1 1 1
Other Plasmodium sp. 1 3 14 1 20
Negative 1 5 1 7
Total 2 1 4 14 6 1 28
Results suggesting the presence of pfhrp2 and/or pfhrp3 deleted parasites in the isolates are shown in the grey fields.
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predominant in 82.3% of the isolates. This low level of diversity
correlates with the general diversity of P. falciparum in French
Guiana and is probably linked to the low transmission level of this
species within this endemic area [6,25]. Some repeats described in
Africa (repeats 11, 13, and 14), South-East Asia/Madagascar
(repeats 13 and 14) were absent in French Guiana [24,26].
Haplotypes 1d and 3 were previously identified in Brazilian
isolates [9]. A correlation between parasitemia and the intensity of
the Pf test band was observed (data not shown). The low number
of isolates in each group did not allow us to evaluate the
correlation between haplotype and RDT sensitivity, and the
literature discussing this point is controversial [11,24,27].
In our study, the M618 P. falciparum isolate was of particular
interest as two different PfHRP2-based (SD Malaria Ag P.f/PanH
and Core MalariaH) kits failed to diagnose it, yet it did not lack
the whole pfhrp2 gene, neither the exon 2 part of the pfhrp3 gene.
The possibility of a prozone effect due to an excess of either
antigen or antibodies was excluded after testing a 1/10 and 1/
100 dilution of the sample (data not shown) [28]. Its pfhrp2
sequence did not exhibit a frame shift, or particular mutations. Its
haplotype was part of the 1 d group composed of two isolates.
The second isolate from this group, with a parasitaemia of 0.66%,
was detectable by the SD Malaria Ag P.f/PanH. With a
parasitaemia of 0.4%, this failure of detection of the M618 could
not therefore be explained by inadequate kit sensitivity. Then, we
calculated the product of the number of type 26 type 7 repeats
as previously described to classify the isolates as sensitive or not to
detection by a PfHRP2 RDT [9]. With a figure of 72, far above
the cut-off point of 43 distinguishing the sensitive isolates, this
isolate should therefore be detectable by HRP2-based RDTs.
Finally, the absence or a low level of expression of the gene
should be considered [29]. However, we were not able to test this
hypothesis without parasites adapted to in vitro propagation or
available RNA extracts.
PfHrp2-based RDTs are Suitable for Malaria Diagnosis in
French Guiana
This study provides important information for laboratories and
health policy makers, as it demonstrates that PfHRP2-based RDTs
are suitable for malaria diagnosis in French Guiana. At a regional
level, human population migration and current knowledge of
parasite diversity (homogeneity of the molecular resistant markers,
genetic diversity…) lead us to believe that this situation should be
the same throughout the Guiana shield [17,25,30,31]. Studies of
pfhrp2 and pfhrp3 deletions among isolates from other countries
located in this region would permit us to verify this assumption. In
the absence of such studies and as parasites lacking the pfhrp2 gene
exist on the continent; a regular control of their prevalence is
required.
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